ArticleThe Journal of antimicrobial chemotherapy2025
A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMycetoma caused by Madurella mycetomatis (eumycetoma) is a neglected tropical disease that forms tumorous lesions in the subcutaneous tissue. The current standard treatment for eumycetoma consists of antifungal treatment combined with surgery, with limited success rates. Due to lack of investment, there are currently no large drug discovery programmes for mycetoma. Repurposing screening can therefore offer an effective and economical way to identify drugs that can be effective in eumycetoma treatment. Therefore, in this study we determined the in vitro activity and in vivo efficacy of 5631 compounds present in the Oncode Drug Repurposing library.
methodsIn total, 5631 drugs from the Oncode Drug Repurposing library were screened for in vitro activity against M. mycetomatis using a CLSI-based in vitro susceptibility assay and CellTiter-Glo as a viability dye. Compounds that inhibited the metabolic activity were tested for in vivo activity in M. mycetomatis-infected Galleria mellonella larvae.
resultsTwenty-eight compounds out of the 5631 drugs were able to inhibit the metabolic activity of M. mycetomatis at 2 µM. Seventeen of the 28 compounds were azoles and 2 were toxic to G. mellonella and therefore not screened further. Two from the remaining 9 compounds, bay117085 (log-rank, P = 0.0494) and IMD-0354 (log-rank, P = 0.0043), prolonged the survival of M. mycetomatis-infected larvae. Both compounds were designed as NF-κB inhibitors.
conclusionsNF-κB inhibitors bay117085 and IMD-0354 were able to prolong the survival of M. mycetomatis-infected larvae.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.